Dur­ing tepid pub­lic mar­ket, Biospring clos­es quar­ter bil­lion dol­lar man­u­fac­tur­ing and tech-fo­cused fund

Much of the hype in biotech cen­ters on the lat­est drug, newest tar­get, or the pa­rade of da­ta. Of­ten side­lined are the tools need­ed to pro­duce those: man­u­fac­tur­ing, di­ag­nos­tic tests, and soft­ware.

Biospring Part­ners wants to fo­cus on the lat­ter and has net­ted $245 mil­lion in its first fund to in­vest in the com­pa­nies that build those tools. The ven­ture cap­i­tal firm was found­ed in 2020 by Michelle Dipp, a sea­soned biotech in­vestor, and Jen­nifer Lum, co-founder of a few tech com­pa­nies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER